Cargando…
Faecal immunochemical tests for the diagnosis of symptomatic colorectal cancer in primary care: the benefit of more than one sample
OBJECTIVE: Faecal immunochemical tests (FITs) are used to screen for colorectal cancer (CRC) and as diagnostic aids in symptomatic patients. However, the number of samples per FIT varies. It is unclear if there is any advantage to analyse multiple-sample FITs in symptomatic patients. DESIGN AND SETT...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730035/ https://www.ncbi.nlm.nih.gov/pubmed/29183266 http://dx.doi.org/10.1080/02813432.2017.1397255 |
_version_ | 1783286289130323968 |
---|---|
author | Högberg, Cecilia Söderström, Lars Lilja, Mikael |
author_facet | Högberg, Cecilia Söderström, Lars Lilja, Mikael |
author_sort | Högberg, Cecilia |
collection | PubMed |
description | OBJECTIVE: Faecal immunochemical tests (FITs) are used to screen for colorectal cancer (CRC) and as diagnostic aids in symptomatic patients. However, the number of samples per FIT varies. It is unclear if there is any advantage to analyse multiple-sample FITs in symptomatic patients. DESIGN AND SETTING: This is a post hoc analysis of a retrospective study that included all cases of CRC and adenomas with high-grade dysplasia (HGD) between 2005 and 2009 in the county of Jämtland, Sweden. SUBJECTS: All patients with CRC and adenomas with HGD that initially presented with symptoms to primary care and delivered FITs. MAIN OUTCOME MEASURE: The likelihood of a positive FIT in cases of CRC and adenomas with HGD; when analysing one, two or three samples. RESULTS: Of 195 patients, 160 delivered three-sample FITs. Using the 139 cases in which at least one sample was positive, the likelihood of detecting a positive sample upon analysis of only one of the three samples was 0.91 (95% CI: 0.85–0.95), indicating that 13 positive cases may have been missed. CONCLUSION: Use of a one-sample FIT instead of a three-sample FIT as a diagnostic aid may result in the missing of one tenth of symptomatic CRCs and adenomas with HGD. |
format | Online Article Text |
id | pubmed-5730035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-57300352017-12-18 Faecal immunochemical tests for the diagnosis of symptomatic colorectal cancer in primary care: the benefit of more than one sample Högberg, Cecilia Söderström, Lars Lilja, Mikael Scand J Prim Health Care Research Articles OBJECTIVE: Faecal immunochemical tests (FITs) are used to screen for colorectal cancer (CRC) and as diagnostic aids in symptomatic patients. However, the number of samples per FIT varies. It is unclear if there is any advantage to analyse multiple-sample FITs in symptomatic patients. DESIGN AND SETTING: This is a post hoc analysis of a retrospective study that included all cases of CRC and adenomas with high-grade dysplasia (HGD) between 2005 and 2009 in the county of Jämtland, Sweden. SUBJECTS: All patients with CRC and adenomas with HGD that initially presented with symptoms to primary care and delivered FITs. MAIN OUTCOME MEASURE: The likelihood of a positive FIT in cases of CRC and adenomas with HGD; when analysing one, two or three samples. RESULTS: Of 195 patients, 160 delivered three-sample FITs. Using the 139 cases in which at least one sample was positive, the likelihood of detecting a positive sample upon analysis of only one of the three samples was 0.91 (95% CI: 0.85–0.95), indicating that 13 positive cases may have been missed. CONCLUSION: Use of a one-sample FIT instead of a three-sample FIT as a diagnostic aid may result in the missing of one tenth of symptomatic CRCs and adenomas with HGD. Taylor & Francis 2017-11-29 /pmc/articles/PMC5730035/ /pubmed/29183266 http://dx.doi.org/10.1080/02813432.2017.1397255 Text en © 2017 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Articles Högberg, Cecilia Söderström, Lars Lilja, Mikael Faecal immunochemical tests for the diagnosis of symptomatic colorectal cancer in primary care: the benefit of more than one sample |
title | Faecal immunochemical tests for the diagnosis of symptomatic colorectal cancer in primary care: the benefit of more than one sample |
title_full | Faecal immunochemical tests for the diagnosis of symptomatic colorectal cancer in primary care: the benefit of more than one sample |
title_fullStr | Faecal immunochemical tests for the diagnosis of symptomatic colorectal cancer in primary care: the benefit of more than one sample |
title_full_unstemmed | Faecal immunochemical tests for the diagnosis of symptomatic colorectal cancer in primary care: the benefit of more than one sample |
title_short | Faecal immunochemical tests for the diagnosis of symptomatic colorectal cancer in primary care: the benefit of more than one sample |
title_sort | faecal immunochemical tests for the diagnosis of symptomatic colorectal cancer in primary care: the benefit of more than one sample |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730035/ https://www.ncbi.nlm.nih.gov/pubmed/29183266 http://dx.doi.org/10.1080/02813432.2017.1397255 |
work_keys_str_mv | AT hogbergcecilia faecalimmunochemicaltestsforthediagnosisofsymptomaticcolorectalcancerinprimarycarethebenefitofmorethanonesample AT soderstromlars faecalimmunochemicaltestsforthediagnosisofsymptomaticcolorectalcancerinprimarycarethebenefitofmorethanonesample AT liljamikael faecalimmunochemicaltestsforthediagnosisofsymptomaticcolorectalcancerinprimarycarethebenefitofmorethanonesample |